GRCE

News

globenewswire.comGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Updateglobenewswire.comJun 18

prnewswire.comGRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firmprnewswire.comJun 11

gurufocus.comGRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firmgurufocus.comJun 8

prnewswire.comGRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firmprnewswire.comJun 8

globenewswire.comGRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc.globenewswire.comJun 3

Trade GRCE

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.

CEO: Prashant Kohli
IPO Date: Feb 7, 2012

Market Data

Open: $2.22
High: $2.38
Low: $2.21
Volume: 274.6K
Avg Volume: 733.6K
52W High: $5.18
52W Low: $1.79

Valuation

Market Cap: $37M
Enterprise Value: $20M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-8.9M
Revenue: $0
Net Income: $-9.5M
Cash: $17M
Debt: $0

Events

EarningsJun 22

EPS est. -0.24